{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T03:31:50Z","timestamp":1793935910214,"version":"4.8.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T00:00:00Z","timestamp":1784160000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T00:00:00Z","timestamp":1791849600000},"content-version":"vor","delay-in-days":89,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"DOI":"10.1186\/s12967-026-08558-4","type":"journal-article","created":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T20:25:41Z","timestamp":1784233541000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Tirzepatide as a therapeutic tool for kidney impairment in obesity: insights from a real-world study"],"prefix":"10.1186","volume":"24","author":[{"given":"Martina","family":"Galasso","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ludovica","family":"Verde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renato","family":"Patrone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Ragozzino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Annunziata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annamaria","family":"Colao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9054-456X","authenticated-orcid":false,"given":"Luigi","family":"Barrea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanna","family":"Muscogiuri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,16]]},"reference":[{"key":"8558_CR1","doi-asserted-by":"crossref","unstructured":"Kovesdy CP. Epidemiology of chronic kidney disease: an update 2022. Kidney Int Suppl (2011). 2022;12(1):7\u201311.","DOI":"10.1016\/j.kisu.2021.11.003"},{"issue":"7","key":"8558_CR2","doi-asserted-by":"publisher","first-page":"e0158765","DOI":"10.1371\/journal.pone.0158765","volume":"11","author":"NR Hill","year":"2016","unstructured":"Hill NR, Fatoba ST, Oke JL, Hirst JA, O\u2019Callaghan CA, Lasserson DS, et al. Global Prevalence of Chronic Kidney Disease - A Systematic Review and Meta-Analysis. PLoS ONE. 2016;11(7):e0158765.","journal-title":"PLoS ONE"},{"key":"8558_CR3","doi-asserted-by":"crossref","unstructured":"Kreiner FF, Schytz PA, Heerspink HJL, von Scholten BJ, Idorn T. Obesity-Related Kidney Disease: Current Understanding and Future Perspectives. Biomedicines. 2023;11(9).","DOI":"10.3390\/biomedicines11092498"},{"key":"8558_CR4","doi-asserted-by":"publisher","first-page":"925619","DOI":"10.3389\/fnut.2022.925619","volume":"9","author":"A Stasi","year":"2022","unstructured":"Stasi A, Cosola C, Caggiano G, Cimmarusti MT, Palieri R, Acquaviva PM, et al. Obesity-Related Chronic Kidney Disease: Principal Mechanisms and New Approaches in Nutritional Management. Front Nutr. 2022;9:925619.","journal-title":"Front Nutr"},{"issue":"3","key":"8558_CR5","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1007\/s10157-025-02804-7","volume":"30","author":"M Mashayekhi","year":"2026","unstructured":"Mashayekhi M, Zuckerman JE, Koubar SH, Wu J, Qing J, Abdipour A, et al. Obesity-related glomerulopathy, A growing kidney burden in the obesity pandemic. Clin Exp Nephrol. 2026;30(3):363\u201372.","journal-title":"Clin Exp Nephrol"},{"key":"8558_CR6","doi-asserted-by":"publisher","first-page":"608397","DOI":"10.1155\/2012\/608397","volume":"2012","author":"J Tang","year":"2012","unstructured":"Tang J, Yan H, Zhuang S. Inflammation and oxidative stress in obesity-related glomerulopathy. Int J Nephrol. 2012;2012:608397.","journal-title":"Int J Nephrol"},{"issue":"2","key":"8558_CR7","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1007\/s13679-023-00500-9","volume":"12","author":"L Verde","year":"2023","unstructured":"Verde L, Luca S, Cernea S, Sulu C, Yumuk VD, Jenssen TG, et al. The Fat Kidney. Curr Obes Rep. 2023;12(2):86\u201398.","journal-title":"Curr Obes Rep"},{"issue":"1","key":"8558_CR8","doi-asserted-by":"publisher","first-page":"e040214","DOI":"10.1136\/bmjopen-2020-040214","volume":"11","author":"S Qin","year":"2021","unstructured":"Qin S, Wang A, Gu S, Wang W, Gao Z, Tang X, et al. Association between obesity and urinary albumin-creatinine ratio in the middle-aged and elderly population of Southern and Northern China: a cross-sectional study. BMJ Open. 2021;11(1):e040214.","journal-title":"BMJ Open"},{"issue":"11","key":"8558_CR9","doi-asserted-by":"publisher","first-page":"2753","DOI":"10.2337\/dci22-0034","volume":"45","author":"MJ Davies","year":"2022","unstructured":"Davies MJ, Aroda VR, Collins BS, Gabbay RA, Green J, Maruthur NM, et al. Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2022;45(11):2753\u201386.","journal-title":"Diabetes Care"},{"issue":"4","key":"8558_CR10","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1038\/s41581-020-00367-2","volume":"17","author":"RZ Alicic","year":"2021","unstructured":"Alicic RZ, Cox EJ, Neumiller JJ, Tuttle KR. Incretin drugs in diabetic kidney disease: biological mechanisms and clinical evidence. Nat Rev Nephrol. 2021;17(4):227\u201344.","journal-title":"Nat Rev Nephrol"},{"issue":"3","key":"8558_CR11","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1056\/NEJMoa2206038","volume":"387","author":"AM Jastreboff","year":"2022","unstructured":"Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, Alves B, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022;387(3):205\u201316.","journal-title":"N Engl J Med"},{"issue":"11","key":"8558_CR12","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1016\/S2213-8587(22)00243-1","volume":"10","author":"HJL Heerspink","year":"2022","unstructured":"Heerspink HJL, Sattar N, Pavo I, Haupt A, Duffin KL, Yang Z, et al. Effects of tirzepatide versus insulin glargine on kidney outcomes in type 2 diabetes in the SURPASS-4 trial: post-hoc analysis of an open-label, randomised, phase 3 trial. Lancet Diabetes Endocrinol. 2022;10(11):774\u201385.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"8558_CR13","doi-asserted-by":"crossref","unstructured":"Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150(9):604\u201312.","DOI":"10.7326\/0003-4819-150-9-200905050-00006"},{"issue":"12","key":"8558_CR14","doi-asserted-by":"publisher","first-page":"5931","DOI":"10.1111\/dom.15967","volume":"26","author":"L Vanek","year":"2024","unstructured":"Vanek L, Kurnikowski A, Krenn S, Mussnig S, Hecking M. Semaglutide in patients with kidney failure and obesity undergoing dialysis and wishing to be transplanted: A prospective, observational, open-label study. Diabetes Obes Metab. 2024;26(12):5931\u201341.","journal-title":"Diabetes Obes Metab"},{"key":"8558_CR15","doi-asserted-by":"crossref","unstructured":"Bruci A, Tuccinardi D, Tozzi R, Balena A, Santucci S, Frontani R et al. Very Low-Calorie Ketogenic Diet: A Safe and Effective Tool for Weight Loss in Patients With Obesity and Mild Kidney Failure. Nutrients. 2020;12(2).","DOI":"10.3390\/nu12020333"},{"issue":"5","key":"8558_CR16","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1046\/j.1523-1755.1998.00898.x","volume":"53","author":"D Fliser","year":"1998","unstructured":"Fliser D, Pacini G, Engelleiter R, Kautzky-Willer A, Prager R, Franek E, et al. Insulin resistance and hyperinsulinemia are already present in patients with incipient renal disease. Kidney Int. 1998;53(5):1343\u20137.","journal-title":"Kidney Int"},{"issue":"4","key":"8558_CR17","doi-asserted-by":"publisher","first-page":"5069","DOI":"10.1002\/j.2040-4603.2023.tb00281.x","volume":"13","author":"VP Parvathareddy","year":"2023","unstructured":"Parvathareddy VP, Wu J, Thomas SS. Insulin Resistance and Insulin Handling in Chronic Kidney Disease. Compr Physiol. 2023;13(4):5069\u201376.","journal-title":"Compr Physiol"},{"issue":"3","key":"8558_CR18","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1007\/s12020-024-03757-9","volume":"84","author":"I Caruso","year":"2024","unstructured":"Caruso I, Giorgino F. Renal effects of GLP-1 receptor agonists and tirzepatide in individuals with type 2 diabetes: seeds of a promising future. Endocrine. 2024;84(3):822\u201335.","journal-title":"Endocrine"},{"issue":"6","key":"8558_CR19","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1016\/S2213-8587(22)00085-7","volume":"10","author":"T Heise","year":"2022","unstructured":"Heise T, Mari A, DeVries JH, Urva S, Li J, Pratt EJ, et al. Effects of subcutaneous tirzepatide versus placebo or semaglutide on pancreatic islet function and insulin sensitivity in adults with type 2 diabetes: a multicentre, randomised, double-blind, parallel-arm, phase 1 clinical trial. Lancet Diabetes Endocrinol. 2022;10(6):418\u201329.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"8558_CR20","doi-asserted-by":"publisher","first-page":"1402583","DOI":"10.3389\/fendo.2024.1402583","volume":"15","author":"S Corrao","year":"2024","unstructured":"Corrao S, Pollicino C, Maggio D, Torres A, Argano C. Tirzepatide against obesity and insulin-resistance: pathophysiological aspects and clinical evidence. Front Endocrinol (Lausanne). 2024;15:1402583.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"9","key":"8558_CR21","doi-asserted-by":"publisher","first-page":"2058","DOI":"10.1111\/dom.14443","volume":"23","author":"JFE Mann","year":"2021","unstructured":"Mann JFE, Buse JB, Idorn T, Leiter LA, Pratley RE, Rasmussen S, et al. Potential kidney protection with liraglutide and semaglutide: Exploratory mediation analysis. Diabetes Obes Metab. 2021;23(9):2058\u201366.","journal-title":"Diabetes Obes Metab"},{"key":"8558_CR22","doi-asserted-by":"crossref","unstructured":"De Fano M, Haurum LL, Schwarz CR, Porcellati F, Andersen A. GIP in Cardiovascular and Kidney Disease: From Physiology to Pharmacology. Diabetes Obes Metab. 2026.","DOI":"10.1111\/dom.70888"},{"issue":"3","key":"8558_CR23","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1038\/s41366-025-01986-0","volume":"50","author":"N Angelopoulos","year":"2026","unstructured":"Angelopoulos N, Androulakis I, Rizoulis A, Boniakos A, Fousteris E, Mentzelopoulou V, et al. A real-world study of tirzepatide for weight loss in adults without diabetes mellitus. Int J Obes (Lond). 2026;50(3):684\u20138.","journal-title":"Int J Obes (Lond)"},{"issue":"3","key":"8558_CR24","doi-asserted-by":"publisher","first-page":"101636","DOI":"10.1016\/j.diabet.2025.101636","volume":"51","author":"ER Hankosky","year":"2025","unstructured":"Hankosky ER, Desai K, Chinthammit C, Grabner M, Stockbower G, He X, et al. Real-world use and effectiveness of tirzepatide among people without evidence of type 2 diabetes in the United States. Diabetes Metab. 2025;51(3):101636.","journal-title":"Diabetes Metab"},{"issue":"3","key":"8558_CR25","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1016\/j.clnu.2018.04.014","volume":"38","author":"R Barazzoni","year":"2019","unstructured":"Barazzoni R, Gortan Cappellari G, Semolic A, Ius M, Zanetti M, Gabrielli A, et al. Central adiposity markers, plasma lipid profile and cardiometabolic risk prediction in overweight-obese individuals. Clin Nutr. 2019;38(3):1171\u20139.","journal-title":"Clin Nutr"},{"issue":"1","key":"8558_CR26","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1186\/s12933-025-02828-z","volume":"24","author":"D Aydos","year":"2025","unstructured":"Aydos D, Aksoy ZB, Unal MA, Akcali KC, Bitirim CV, Turan B. The dual GLP-1 and GIP receptor agonist tirzapetide provides an unintended interaction with the beta-adrenoceptors and plays a role in glucose metabolism in hyperglycemic or senescent cardiac cells. Cardiovasc Diabetol. 2025;24(1):338.","journal-title":"Cardiovasc Diabetol"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12967-026-08558-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-026-08558-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-026-08558-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T01:48:09Z","timestamp":1791856089000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12967-026-08558-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,16]]},"references-count":26,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["8558"],"URL":"https:\/\/doi.org\/10.1186\/s12967-026-08558-4","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,16]]},"assertion":[{"value":"1 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study has been approved by the Local Ethical Committee and carried out in accordance with the Code of Ethics of the World Medical Association (Declaration of Helsinki) for experiments that involved humans. The aim of the study was clearly explained to all the study participants and a written informed consent was obtained.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"1291"}}